Comparison of Lenvatinib with radiofrequency ablation and radiofrequency ablation alone with radiofrequency ablation planned hepatocellular carcinoma : randomized, prospective, multicenter trial - Trial UMIN000051126
Access comprehensive clinical trial information for UMIN000051126 through Pure Global AI's free database. This phase not specified trial is sponsored by SHIN-YURIGAOKA General Hospital and is currently Enrolling by invitation. The study focuses on Hepatocellular carcinoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
UMIN000051126
Enrolling by invitation
drug
Trial Details
University Hospital Medical Information Network • UMIN000051126
Comparison of Lenvatinib with radiofrequency ablation and radiofrequency ablation alone with radiofrequency ablation planned hepatocellular carcinoma : randomized, prospective, multicenter trial
Lenvatinib - radiofrequency ablation study
Study Focus
Sponsor & Location
SHIN-YURIGAOKA General Hospital
Japan
Timeline & Enrollment
N/A
May 12, 2023
N/A
ICD-10 Classifications
Malignant neoplasm: Hepatoblastoma
Malignant neoplasm: Liver cell carcinoma
Malignant neoplasm: Other specified carcinomas of liver
Malignant neoplasm: Liver, unspecified
Malignant neoplasm: Hepatic flexure
Data Source
University Hospital Medical Information Network
UMIN000051126
Non-Device Trial